Clinical Studies Completed for HeartVue's 6S Heart Screening System
Posted on: Monday, 18 August 2008, 09:01 CDT
Pegasus/Heartview LLC (PINKSHEETS: PGUZ) today announced that they have now completed the required clinical studies, which are an integral part of the process required for the marketing of the Company's breakthrough HeartVue 6S Heart Screening System in North America.
The clinical studies, held from April to July 2008, were completed in accordance to the guidelines and recommendations set forth by the FDA's Section 510K Pre-Market Notification of Intent To Market, and includes test results of 170 patients of various ages, genders, races, weights and health conditions. The test results will now be analyzed, interpreted and presented to the FDA in the form of a 510K Filing. The HeartVue 6S Screening System has already obtained a CE Mark Approval in Europe in November 2006.
The HeartVue 6S Screening System provides a quick (1-2 minutes) and accurate assessment of patients with suspected coronary artery disease. The device uses only 4 standard electrodes and a dispersion mapping method analysis of low amplitude ECG signals to detect heart abnormalities and ischemia. The results are then presented as a color-coded, 3-dimensional digital heart map which reflects electrical dispersions. The device allows the tester to observe the condition of the heart muscle, as well as the intensity of the heart stress load. The test uses new information from ECG fluctuations that are usually ignored as "noise" by regular ECG devices. An image of the patient's heart, along with an electrocardiogram are produced. The HeartVue 6S System will be an invaluable screening tool for cardiologists, general practitioners, clinics, hospitals, the fitness industry, sports teams and emergency medical facilities.
For more information, please contact Paul Davey, Investor Services, at 778-389-0915 or Email: paul@pegasusbiosciences.com, or contact Daniel P. Kesonen, Chairman & CEO, at 561-626-9901. Visit the Company's website: www.pegasusbiosciences.com
Pegasus Pharmaceuticals adheres to the statutes and provisions of the Safe Harbor Act.
Contacts: Paul Davey Investor Services 778-389-0915 paul@pegasusbiosciences.com Daniel P. Kesonen Chairman & CEO 561-626-9901 www.pegasusbiosciences.com
SOURCE: Pegasus Pharmaceuticals Inc.
Source: MARKET WIRE
Related Articles
- Novellus Systems Reports Fourth Quarter and Year-End Results
- 'Employment Screening Behavior Integrity Test Would Have Labeled Gov. Blagojevich 'NOT QUALIFIED',' Says Merchants Information Solutions CEO
- Advantest Kyushu Systems Introduces ADS1911 Analog Test System
- SunLink Health Systems, Inc. Announces Fiscal 2009 First Quarter Results
- Legacy Heart Center: New Screening Tests Can Detect Heart Problems Before They Are Life-Threatening
- World-Renowned Cardiac Surgeon States Heart Smart System(TM) May Save Your Life
- Board Revisits Drug Tests for Teachers: Schools to Look at How Other Systems Screen
- Associations Between Obesity and Receipt of Screening Mammography, Papanicolaou Tests, and Influenza Vaccination: Results From the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study
- American Scientific Resources Commences Production of Infomercial for Its Revolutionary Heart Smart System(TM)
- Micrel Purchases Multiple Credence ASL 3000 and ASL 1000 Systems for Mixed-Signal Test
 |
 |
User Comments (0)
RSS Feeds